Introduction to David English, VP of Business Development

VP of Business Development at Poolbeg Pharma, David English, gives an overview of his experience and why he decided to join the Poolbeg Pharma team.

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Click to view all articles for the EPIC:
Or click to view the full company profile:
Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn

More articles like this

Poolbeg Pharma releases positive data from influenza trial

Poolbeg Pharma has released new data from a human challenge trial that shows its treatment has strong potential in dampening inflammation in blood and tissues in influenza and other viral infections. POLB 001 showed success in reducing multiple markers

Poolbeg Pharma granted patent by USPTO for POLB 001

Poolbeg Pharma plc (LON:POLB, OTCQB: POLBF),  a leading infectious disease focused biopharmaceutical company, has announced that further to its announcement on 4 October 2022, it has been granted a patent by the US Patent and Trademark Office (USPTO) for methods of treating hypercytokinaemia

Positive results from Poolbeg Pharma’s human challenge trial

Poolbeg Pharma – a company focused on developing infectious disease therapies – has announced data from its bacterial lipopolysaccharide (LPS) human challenge trial for POLB 001. The treatment is a viral strain agnostic, small molecule immunomodulator which is

SLAS2023: We have the building blocks, onto the building

In the time that has passed since SLAS2022 in Boston, USA, the drug discovery industry has had to deal with all manner of external obstacles, from the war in Ukraine, to how Brexit has changed the world’s relationship

The small drug firms set to benefit from RSV vaccines

Here’s an investment idea that starts with large blue-chip companies, but has significant trickle-down potential to at least three smaller, growth companies listed in the UK. Chances are RSV, or respiratory syncytial virus, which has symptoms similar to

Poolbeg Pharma Investment Case

Poolbeg Pharma (LON:POLB / OTCQB:POLBF) Investment Case with CEO Jeremy Skillington. Poolbeg Pharma is a clinical stage infectious disease pharmaceutical company with a unique capital light model. The company is focus on targeting the significant global medical need to treat

AI continues to gain momentum in the biopharmaceutical industry in 2023

While the biopharmaceutical industry has been impacted and pressured by various factors such as the Covid-19 pandemic, inflation, the Ukraine-Russia war, ongoing supply chain issues, and a challenging economic environment, collaboration between pharma companies and emerging technologies providers

Elaine Sullivan on International Day of Women & Girls in Science

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Donegal man hopes to raise $1 billion in Nasdaq launch

A Donegal man hopes to raise one billion dollars when his latest venture launches on New York’s Nasdaq. Poolbeg Pharma is planning to list on the stock exchange as chairman Cathal Friel (58), from Creeslough, eyes another $1bn

The race to supercharge cancer-fighting T cells

CAR-T therapies capitalize on the activities of T cells, the immune system’s natural hunters that prowl through the body looking for things that don’t belong. Foreign cells, or those infected with a virus, express unusual proteins that serve

AI continues to gain momentum in the biopharmaceutical industry in 2023

While the biopharmaceutical industry has been impacted and pressured by various factors such as the Covid-19 pandemic, inflation, the Ukraine-Russia war, ongoing supply chain issues, and a challenging economic environment, collaboration between pharma companies and emerging technologies providers

Poolbeg Pharma strategic expansion of POLB 001 into oncology

Poolbeg Pharma plc (LON:POLB), a leading infectious disease focused biopharmaceutical company, has announced the strategic expansion of POLB 001 into oncology. While investigating the role of cytokine release syndrome in severe influenza, Poolbeg discovered data specific to the overt immune

Licensing deal could pave way for new treatments for metabolic diseases

In a proof-of-concept clinical trial, Poolbeg Pharma will look into the potential of microencapsulation and nanoencapsulation oral delivery technologies. Poolbeg Pharma has acquired a licence from a sister company of Cork start-up AnaBio Technologies for an innovative treatment

No more posts to show